XP Inc. (XP) Stock News

The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (0.35%) and holds only 65 positions. Both funds have significantly underperformed the S&P 500 over five years, reflecting the challenges of biotech and pharmaceutical investing.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.

LXP Industrial Trust announced a quarterly common share dividend of $0.70 per share payable on July 15, 2026, for the quarter ending June 30, 2026. The REIT also declared a dividend of $0.8125 per share for its Series C Cumulative Convertible Preferred Stock payable on August 17, 2026.

Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with greater than 50% reduction in death risk, though it did not meet the secondary symptom score endpoint. The safety profile was manageable with no new safety signals observed.

GREENWICH, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO ), a leading provider of freight transportation in North America, today reported certain preliminary LTL segment operating metrics for May 2026. LTL tonnage per day increased 0.5%, as compared with May 2025, attributable to a year-over-year increase of 3.3% in shipments per day and a decrease of 2.7% in weight per shipment. Actual results for May 2026 may vary from the preliminary results reported above. About XPO XPO, Inc. (NYSE: XPO ) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company's customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 594 locations and 37,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn , Facebook , X , Instagram and YouTube . Forward-looking Statements This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as "anticipate," "estimate," ... Full story available on Benzinga.com

NRx Pharmaceuticals announced a proposed underwritten public offering of common stock, causing shares to plummet 19.05% to $3.74 in after-hours trading on Tuesday. The clinical-stage biopharmaceutical company, which develops treatments for CNS disorders including suicidal depression and PTSD, plans to use the net proceeds for working capital and general corporate purposes. BTIG LLC is acting as lead bookrunner for the offering.

Q1 Revenue Up 44% YoY; Same-Store Sales Up 29%; Adjusted EBITDA Turns Positive as Company Advances National Expansion Strategy EDMONTON, AB , June 1, 2026 /CNW/ - Dr. Phone Fix Canada Corporation (TSXV: DPF) ("Dr. Phone Fix" or the "Company"), one of Canada's fastest-growing and award-winning consumer electronics repair and resale platforms, today reported financial results for the three months ended March 31, 2026, and provided an update on recent corporate developments. The Company operates a network of 44 corporately owned stores across five Canadian provinces. Financial Results Summary (CAD) (all dollar amounts in 000's) Three Months Ended Mar 31, 2026 Three Months Ended Mar 31, 2025 Variance (%) Revenue 3,162 2,196 +44 % Gross Profit 1,621 1,210 +34 % Gross Margin 51.3 % 55.1 % -3.8 pp Operating Expenses (SG&A) 2,476 1,754 +41 % Adjusted EBITDA(1) 88 (13) n/m Cash 291 1,558 -81 % (1) See Non-GAAP Financial Measure towards the end of this document. "Q1 reflected continued progress in the execution of our strategy with revenue increasing 44% year-over-year and comparable-store sales increasing 29%, even in what is typically our seasonally weakest quarter," said Piyush Sawhney, Founder and Chief Executive Officer of Dr. Phone Fix. "We also delivered positive Adjusted EBITDA, generated positive operating cash flow, and continued to improve execution across our national network while integrating recently acquired locations and advancing our OEM, insurance, supplier, repair and certified pre-owned device programs." Mr. Sawhney continued, "We have spent the past year building the foundation for a national, carrier-neutral device lifecycle platform. Today, we have 44 corporately owned locations across five provinces, a growing pipeline of acquisition and greenfield opportunities, and a strategy focused on disciplined expansion and stronger unit-level economics throug

First-quarter revenue totaled RMB 13.03 billion. Quarterly gross margin reached 20.6%. Overseas deliveries surpassed 6,000 units for the first time in April, targeting sustained monthly overseas deliveries above 10,000 units in Q4. The Ultra trim took over 80% of early GX orders, becoming one of the most popular choices in the premium segment market in China. In April, ADAS mileage penetration on VLA 2.0-equipped XPENG vehicles surpassed 50% for the first time. VLA 2.0 is currently under testing in Europe. GUANGZHOU, China , May 28, 2026 /PRNewswire/ -- XPENG, a leading Chinese AI-driven technology company, today announced its financial results for the first quarter of 2026. Accelerating Physical AI Commercialization: VLA 2.0, Robotaxi and Humanoid Robotics in Full Swing During the earnings call, He Xiaopeng, Chariman & CEO, detailed the company's ongoing transformation from an automotive manufacturer into a global leader in physical AI world. VLA 2.0: VLA 2.0, which saw its ADAS mileage penetration rate on XPENG vehicles exceed 50% for the first time in April, is now being tested in Europe. Robotaxi: XPENG GX fleet is already conducting L4 public-road testing in Guangzhou ahead of Robotaxi pilot operations in Q3. The GX's L4 full-redundancy ... Full story available on Benzinga.com

XPeng Inc. (NYSE: XPEV ) stock traded mostly flat Thursday after the company reported first-quarter financial results. Revenue Growth and Deliveries The company reported quarterly revenue of 13.03 billion Chinese yuan ($1.89 billion), down 17.6% year over year and below the analyst consensus estimate of $3.13 billion . Revenue declined 41.4% from the previous quarter. The Tesla Inc. (NASDAQ: TSLA ) rival delivered 62,682 vehicles during the quarter, down 33.3% from a year earlier. As of March 31, 2026, XPeng's physical sales network included 733 stores across 256 cities. The company's self-operated charging network expanded to 3,455 stations, including 2,398 ultra-fast charging stations. Margins, Profitability and Balance Sheet Revenue from vehicle sales fell 23.5% year over year to 11 billion yuan ($1.59 billion), primarily due to lower vehicle deliveries. Gross margin improved to 20.6% from 15.6% a year earlier. Vehicle margin rose to 12.1% from 10.5% in ... Full story available on Benzinga.com

<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Cash position</i><i xmlns="http://www.w3.org/1999/xhtml"><sup xmlns="http://www.w3.org/1999/xhtml">[i]</sup></i><i xmlns="http://www.w3.org/1999/xhtml"> was RMB42.09 billion (US$6.10 billion) as of March 31, 2026</i></li> <li xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Quarterly total revenues were RMB13.03 billion, a 17.6% decrease year-over-year</i></li> <li xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Quarterly gross margin was 20.6%, an increase of 5.0 percentage points over the same period of 2025</i></li> <li xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Quarterly vehicle margin was 12.1%, an increase of 1.6 percentage points over the same period of 2025</i></li> </ul> <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">GUANGZHOU, China</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 28, 2026</span> /PRNewswire/ -- XPeng Inc. (&#34, <b xmlns="http://www.w3.org/1999/xhtml">XPENG</b>&#34, or the &#34, <b xmlns="http://www.w3.org/1999/xhtml">Company</b>, &#34, ("<b xmlns="http://www.w3.org/1999/xhtml">XPENG</b>" or the "<b xmlns="http://www.w3.org/1999/xhtml">Company</b>,"

Mission Bank has expanded its Bakersfield-based Agricultural Lending Team by hiring three industry veterans: Relationship Managers John Etchison and Eric Schoenheide, and Relationship Associate Eliza Hernandez. The team brings nearly 75 years of combined experience in ag lending and will operate from the Downtown Bakersfield Business Banking Center under Ag Division Manager Rob Hallum. This marks the second new team added by Mission Bank in 2026.

Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO AUSTIN, Texas — May 26, 2026 — MedX Holdings, Inc. (OTC: MEDH ) (soon to be Dazed Inc., pending ticker symbol DAZE), a dynamic brands and acquisition company focused on the emerging hemp, cannabis, and hospitality industries, today announced its financial results for the first quarter ended March 31, 2026. The company is thrilled to report significant year-over-year revenue and gross profit growth, continued profitability, and major traction in its nationwide franchise expansion. Q1 2026 Financial Highlights: Accelerated Growth and Profitability The first quarter of 2026 reflects the power of MedX's strategic focus on high-margin branding, efficient operations, and calculated expansion. Key financial milestones from the Q1 2026 consolidated financial statements include: Solid Revenue Growth: Q1 2026 revenues reached $521,874, representing an impressive 52.7% increase compared to revenues of $341,711 in Q1 2025. Surging Gross Profit: Gross profit for the quarter climbed to $398,990, a 70.6% jump from the $233,793 reported in the same period last year. Sustained Profitability: The company maintained a positive bottom line, reporting a net income of $22,203 for the three months ended March 31, 2026. Expansion on Track: Bringing the "Third Place" to New Cities Following the momentum built in late 2025, ... Full story available on Benzinga.com

MedX Holdings announced Q1 2026 results with continued net profitability and debt reduction. The company is rebranding to Dazed Inc. (ticker: DAZE) and expanding with three new LazyDaze + Coffeeshop locations in San Marcos, Houston, and Baltimore. The company is also finalizing partnerships for Lazydaze Coffee and K-Cup products and capitalizing on cannabis's federal reclassification to Schedule III.

Five Iron Golf opened its first Texas location in Fort Worth's Near Southside district, celebrating with tournament-week specials tied to the Charles Schwab Challenge at Colonial Country Club. The 10,000-square-foot venue features 12 Trackman simulators, a full-service bar, and entertainment amenities. Special offers include complimentary simulator time for anyone named Charles and appetizers for tournament attendees.

Austin, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- MEDX HOLDINGS ANNOUNCES Q1 2026 HIGHLIGHTS, MULTI-CITY EXPANSION, AND CORPORATE ACTION TO REBRAND AS DAZED INC. (TICKER: DAZE) AUSTIN, Texas — May 22, 2026 — MedX Holdings, Inc. (OTC: MEDH ), a leader in the converging cannabis, hemp, and hospitality sectors, today announced its operational and financial highlights for the first quarter of 2026. Building on the net profitability achieved in Q4 2025, the company continues to execute its aggressive expansion strategy, marked by upcoming store openings, strategic product partnerships, and a major corporate rebranding initiative to align with its rapidly growing consumer footprint. Corporate Action: Rebranding to Dazed Inc. To align the company's corporate identity with its flagship consumer brands and long-term vision, MedX Holdings has announced its intention and initiated the required corporate actions to change its name to Dazed Inc. Alongside this name change, the company intends to request a formal ticker symbol change to DAZE . This strategic evolution reflects the company's dominant focus on scaling the Lazydaze franchise ecosystem and Dazed Distribution networks. Q1 Financial and Operational Milestone Highlights Continued Debt Reduction: MedX sustained its disciplined focus on balance sheet strength, further paring down long-term liabilities throughout Q1 to enhance cash flow and shareholder equity. Lazydaze Coffee & K-Cup Partnerships: The company is currently in the final stages of talks with potential strategic partners to massively scale ... Full story available on Benzinga.com

U.S. stock futures declined on Tuesday as inflation concerns weighed on markets. The S&P 500 and Nasdaq 100 fell slightly, with the 10-year Treasury yield at 4.60%. Key movers included XP Inc. dropping 6% on weak earnings, Atmos Energy surging 10% after strong Q2 results and dividend increase, and GE Aerospace gaining on a Japan Airlines maintenance deal. Analysts warn the Fed may shift to a tightening bias if inflation pressures persist.

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures were lower as the Nasdaq 100 index fell on Tuesday following Monday’s mixed close. Inflation fears gripped Wall Street as Ed Yardeni anticipated an imminent policy shift, noting that recent CPI and PPI data suggest the Fed is currently "behind the curve" on inflation. He expects the central bank to completely drop its easing stance and adopt a "tightening bias" at its upcoming June meeting, followed by a 25-basis-point rate hike in July. Meanwhile, the 10-year Treasury bond yielded 4.60%, and the two-year bond was at 4.06%. The CME Group's FedWatch tool ‘s projections show markets pricing a 98.8% likelihood of the Federal Reserve leaving the current interest rates unchanged during June’s meeting. Index Performance (+/-) Dow Jones -0.02% S&P 500 -0.13% Nasdaq 100 -0.24% Russell 2000 -0.09% The SPDR S&P 500 ETF Trust (NYSE: SPY ) and Invesco QQQ Trust ETF (NASDAQ: QQQ ) , which track the S&P 500 and Nasdaq 100, respectively, were lower in premarket on Tuesday. The SPY was down 0.45% at $735.36, while the QQQ was lower by 0.84% to $699.96. data-variant="banner" data-news-mode="manual" > Read Also: Nvidia Is Still 'Cheapest Name' In Tech, Says Market Strategist: Q1 Earnings Will Make Your 'Jaw Drop' Stocks In Focus XP XP Inc. (NASDAQ: XP ) was 6% lower in premarket on Tuesday as it reported worse-than-expected first-quarter financial results. The company also named Gustavo Alejo Viviani as CFO starting Aug. 3. Benzinga’s Edge Stock Rankings indicate that XP maintains a weak price trend in the long term, short, and medium terms, with a solid value score. Full story available on Benzinga.com

XPeng stock declined 3.49% to $15.07 on Monday despite unveiling its first mass-produced Robotaxi built on proprietary technology, with pilot operations planned for H2 2026 and full autonomy by early 2027. April deliveries reached 31,011 vehicles (up 13% MoM but down 11.5% YoY), while the company targets humanoid robot production in Q4 2026 and has received 7,000 flying car orders. The stock trades 7.3% below its 20-day SMA and 23.9% below its 200-day SMA, with analysts maintaining a Hold rating and $21.06 price target.

XPeng Inc. (NYSE: XPEV ) stock is trading lower on Monday as the company disclosed the official rollout of its first mass-produced Robotaxi, which is a significant step in its autonomous vehicle strategy. This news comes during a mixed market day, with major indices like the Nasdaq down by 0.72%, indicating broader market pressures that may be influencing the stock’s performance. • XPeng stock is testing key support levels. Why is XPEV stock at lows? XPeng Robotaxi Rollout XPeng’s newly unveiled Robotaxi, built on the XPENG GX platform, is China’s first production-ready model developed entirely with in-house technologies. The company plans to initiate pilot operations in the second half of this year, aiming for fully autonomous operations by early 2027. April Deliveries  Recently, the company reported  April deliveries  of 31,011 vehicles, up 13% month over month but down 11.5% year over year. The company said customer engagement improved following the rollout of its Vision-Language-Action (VLA) 2.0 system in March, with test-drive satisfaction rising by the end of April. The average time to make purchase decisions after test drives declined 44.7% month over month, underscoring intelligent driving as a key sales driver. Future Mobility Push Beyond vehicles, XPeng is advancing new ... Full story available on Benzinga.com

NRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-assisted TMS. The company also won a bid to acquire Geneuro's HERV-targeting asset portfolio and expanded its HOPE Therapeutics clinic network to five locations.

Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable preliminary determinations already received from the FDA Office of Generic Drugs on bioequivalence, labeling, drug product, drug substance, and safety. Initiation of commercial manufacturing of Ketamine at the 1 million dose per month level with recent FDA inspection of the manufacturing facility and granting of inspection status consistent with launch of an ANDA drug. Completed a Type C meeting with the FDA Division of Psychiatry Products and CDER leadership, in which the Agency expressed openness to existing clinical trial data and Real World Evidence supporting approval without additional trials. Presidential Executive Order signed and Congressional Appropriations Language filed encouraging the use of Real World Evidence in the approval of drugs for suicidal depression and PTSD. Appointment of Prof. Joshua Brown, MD, PhD (Harvard/McLean) as Chief Medical Innovation Officer, bringing NIH- and DARPA-funded expertise in D-cycloserine and TMS for depression, PTSD, and suicidality. FDA acceptance of an Investigational New Drug (IND) application for NRX-101 as an adjunct to robotic-enabled Transcranial Magnetic Stimulation (TMS), with anticipated non-dilutive federal funding supporting study at military and civilian sites. Development of a patentable, sustained-release formulation of D-cycloserine designed to enhance TMS efficacy, building on prior trial data showing a doubling of clinical response and 8-fold increase in remission versus standard TMS. First revenue generated from five interventional psychiatry clinics treating severe depression and PTSD, with funding from the VA, Department of War, private insurers, and self-pay; footprint expected to expand m

Falcon Gold Corp. announced a corporate restructuring to optimize its capital structure and strengthen market positioning. The company is refocusing its strategy on its northwestern Ontario portfolio, particularly the Central Canada Gold Project in the Atikokan gold camp, where it plans to conduct up to 20 diamond drill holes. The company abandoned its proposed acquisition of Newfoundland claims and entered a CAD $100,000 marketing agreement with AGORACOM. Management believes current macroeconomic conditions and strengthening gold prices support junior gold exploration companies in Tier-1 jurisdictions.

INmune Bio Inc. (NASDAQ: INMB) announced that Phase 2 MINDFuL trial results for XPro™ (XPro1595, pegipanermin) in mild Alzheimer's disease with inflammation have been published in NPJ Dementia. In a pre-specified enriched subgroup (n=100) with amyloid-beta positivity and inflammation biomarkers, XPro™ showed directionally consistent benefits across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks with no serious adverse events. The company received FDA Fast Track designation for the program.

INmune Bio announced that the FDA has granted Fast Track designation to XPro (pegipanermin), a first-in-class selective soluble TNF inhibitor, for treating early Alzheimer's disease including mild cognitive impairment and mild dementia. The designation facilitates expedited development and review, recognizing the urgent need for treatments addressing neuroinflammation in Alzheimer's. The company plans to execute a Phase 2b/3 precision-medicine registrational program targeting patients with biomarkers of inflammation.

NRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in development. NRX-100 has received Fast Track Designation and NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.

eXp World reported Q1 2026 results with improved profitability metrics including adjusted EBITDA of $4.1 million (up 88% YoY) and gross profit of $75.3 million. The company acquired NextHome, a franchise platform, to expand into independent brokers and franchises with higher margins. Management reiterated full-year 2026 guidance citing macroeconomic uncertainty, while highlighting investments in technology, the SUCCESS personal development platform, and international expansion as growth drivers.

Trio Petroleum Corp announced it has raised approximately $24 million through its ATM equity program, strengthening its balance sheet. The company is now pursuing a growth strategy focused on acquiring Canadian oil and gas assets, which management believes offer attractive valuations and operational upside. The CEO emphasized the company has transitioned from stabilization to execution phase and is urging stockholder support at the May 21, 2026 annual meeting.